Jeaninne Lacroix

Title: Jeaninne Lacroix: Innovator in Oncolytic Virotherapy

Introduction

Jeaninne Lacroix is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of cancer treatment, particularly through her innovative work in oncolytic virotherapy. Her research focuses on developing therapies for mesenchymal tumors, including Ewing's sarcoma.

Latest Patents

Jeaninne Lacroix holds a patent for her invention titled "Oncolytic virotherapy for the therapy of Ewing's sarcoma." This invention relates to a parvovirus designed for the treatment of malignant bone tumors, specifically targeting localized and metastasized bone tumors such as osteosarcoma and Ewing's sarcoma. The preferred parvovirus utilized in her research is the replication competent parvovirus H-1PV. She has successfully secured 1 patent for this groundbreaking work.

Career Highlights

Lacroix is affiliated with the Deutsches Krebsforschungszentrum, a leading cancer research center in Germany. Her role at this institution has allowed her to collaborate with other experts in the field and contribute to advancements in cancer therapies.

Collaborations

Throughout her career, Jeaninne has worked alongside notable colleagues, including Zoltan Kis and Barbara Leuchs. Their collaborative efforts have furthered research in oncolytic virotherapy and enhanced the understanding of treatment options for aggressive tumors.

Conclusion

Jeaninne Lacroix's innovative work in oncolytic virotherapy represents a significant advancement in the treatment of Ewing's sarcoma and other malignant bone tumors. Her contributions to cancer research continue to inspire and pave the way for future developments in the field.